REFERENCES
|
Aguayo-Orozco, A., Taboureau, O., Brunak, S. |
The use of systems biology in chemical risk assessment. Current Opinion in Toxicology, 15:48–54. (2019) |
|
|
Knapen, D., Angrish, M.E., Fortin, M.C., Katsiadaki, I., Leonard, M., Margiotta-Casaluci, L., Munn, S., O’Brien, J.M., Pollesch, N., Cody Smith, L., Zhang, X., Villeneuve, D.L. |
Adverse Outcome Pathway Networks I: Development and Applications. Environmental Toxicology and Chemistry, 37(6):1723-1733. (2018) |
|
|
Organisation for Economic Cooperation and Development (OECD), Series on Adverse Outcome Pathways |
Users’ Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways. OECD Series on Adverse Outcome Pathways, No. 1, OECD Publishing, Paris. (2018) |
|
|
Sewell, F., Gellatly, N., Beaumont, M., Burden, N., Currie, R., de Haan, L., Hutchinson, T.H., Jacobs, M., Mahony, C., Malcomber, I., Mehta, J., Whale, G., Kimber, I. |
The future trajectory of adverse outcome pathways: a commentary. Archives of Toxicology, 92(4):1657-1661. (2018) |
|
Bal-Price, A., Lein, P. J., Keil, K. P., Sethi, S., Shafer, T., Barenys, M., Fritsche, E., Sachana, M., Meek, M.E.B. |
Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. NeuroToxicity 59: 240-255. (2017) |
|
|
Bal-Price, A., and Meek, M.E. |
Adverse outcome pathways: Application to enhance mechanistic understanding of neurotoxicity. Pharmacology & Therapeutics, 179: 84 – 95. (2017) |
|
|
Hartung, T., FitzGerald, R.E., Jennings, P., Mirams, G.R., Peitsch, M.C., Rostami-Hodjegan, A., Shah, I., Wilks, M.F., Sturla, S.J. |
Systems Toxicology: Real World Applications and Opportunities. Chemical Research in Toxicology, 2017, 30, 870-882. (2017) |
|
|
Langley, G. R., Adcock, I. M., Busquet, F., Crofton, K.M., Csernok, E., Giese, C., Heinonen, T., Hofmann-Apitius, M., Landesmann, B., Marshall, L.J., McIvor, E., Muotri, A.R., Noor, F., Schutte, K., Seidle, T., van de Stolpe, A., Van Esch, H., Willett, C., Woszczek, G. |
Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations. Drug Discovery Today, 22(2):327-339. (2017) |
|
|
National Academies of Sciences, Engineering, and Medicine (NASEM) |
Using 21st Century Science to Improve Risk-Related Evaluations. Washington, DC: The National Academies Press. (2017) |
|
|
Organisation for Economic Cooperation and Development (OECD) |
Revised Guidance Document on Developing and Assessing Adverse Outcome Pathways. Series on Testing and Assessment No. 184, ENV/JM/MONO(2013)6 , OECD Publishing, Paris. (2017) |
|
|
Organisation for Economic Cooperation and Development (OECD) |
Guidance Document on the Reporting of Defined Approaches and Individual Information Sources to be used within Integrated Approaches to Testing and Assessment (IATA) for Skin Sensitisation. Series on Testing and Assessment No. 256, ENV/JM/MONO(2016)29, OECD Publishing, Paris. (2016) |
|
|
Organisation for Economic Cooperation and Development (OECD) |
Guidance Document for the Use of Adverse Outcome Pathways in Developing Integrated Approaches to Testing and Assessment. Series on Testing & Assessment No. 260, ENV/JM/MONO(2016)67, OECD Publishing, Paris. (2016) |
|
|
Sachana M, and Leinala, E. |
Approaching Chemical Safety Assessment Through Application of Integrated Approaches to Testing and Assessment: Combining Mechanistic Information Derived from Adverse Outcome Pathways and Alternative Methods. Applied In Vitro Toxicology, 3(3):227-233. (2017) |
|
Institute of Medicine |
Improving and Accelerating Therapeutic Development for Nervous System Disorders: Workshop Summary. Washington, DC: The National Academies Press. (2014) |
|
|
Mc Auley, M.T., Choi, H., Mooney, K., Paul, E., Miller, V.M. |
Systems Biology and Synthetic Biology: A New Epoch for Toxicology Research, Hindawy, Advances in Technology, 15. (2015) |
|
|
Meek, M.E., Boobis, A., Cote, I., Dellarco, V., Fotakis, G., Munn, S., Seed, J., and Vickers, C. |
New developments in the evolution and application of the WHO/IPCS framework on mode of action/species concordance analysis. J Appl Toxicol. 34(1):1-18. (2014) |
|
|
Pound, P, and Bracken, M. B. |
Is animal research sufficiently evidence based to be a cornerstone of biomedical research? BMJ 348, g3387. (2014) |
|
|
Sturla, S.J., Boobis, A.R., FitzGerald, R.E., Hoeng, J., Kavlock, R.J., Schirmer, K., Whelan, M., Wilks, M.F., Peitsch, M.C. |
Systems Toxicology: From Basic Research to Risk Assessment. Chemical Research in Toxicology, 27, 314-329. (2014) |
|
Boobis, A. R., Cohen, S. M., Dellarco, V., McGregor, D., Meek, M.E., Vickers, C., Willcocks, D., Farland, W. |
IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol. 36(10), 781-792. (2006) |
|
|
Boobis, A. R., Doe, J. E., Heinrich-Hirsch, B., Meek, M.E., Munn, S., Ruchirawat, M., Schlatter, J., Seed, J., Vickers, C. |
IPCS framework for analyzing the relevance of a noncancer mode of action for humans. Crit Rev Toxicol 38, 87-96. (2008) |
|
|
Clewell, H. J., Gentry, P. R., Gearheart, J. M., Allen, B.C., Andersen, M.E. |
Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene. Chemosphere, 31, 2561-2578. (1995) |
|
|
Meek, M., Bucher, J., Cohen, S., Dellarco, V., Hill, R.N., Lehman-McKeeman, L.D., Longfellow, D.G., Pastoor, T., Seed, J., Patton, D.E. |
A Framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol 2003; 33, 591 – 653. (2003) |
|
|
National Research Council (NRC). |
Toxicity testing in the 21st century: a vision and a strategy. Washington, DC: National Academy of Sciences. (2007) |
|
|
Organisation for Economic Cooperation and Development (OECD) |
Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. Series on Testing and Assessment, No. 138, OECD Publishing, Paris. (2011) |
|
|
Organisation for Economic Cooperation and Development (OECD) |
The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins, Part 1: Scientific Evidence. Series on Testing and Assessment, No.168, OECD Publishing, Paris. (2012) |
|
|
Plenge, R.M., Scolnick, E.M., Altshuler, D. |
Validating therapeutic targets though human genetics. Nat. Dev. Drug Discov. 12:581-594. (2013) |
|
Bradford Hill, A. |
The Environment and Disease: Association or Causation? Proc R Soc Med, 58:295-300. (1965) |